Ultragenyx ORBIT Phase III misses fracture endpoint, sparking RARE shareholder class actions

Ultragenyx faces scrutiny after Phase III ORBIT misses fracture endpoint

ORBIT trial outcome and company statements come under legal challenge

Ultragenyx Pharmaceutical is facing litigation after its Phase III ORBIT study in patients with Osteogenesis Imperfecta (OI) fails to achieve a statistically significant reduction in annualized fracture rate (AFR), according to recent class action complaints. Plaintiffs contend the company made materially misleading public statements about its understanding of the drug candidate’s effects in OI patients, and that those statements are undermined by the ORBIT results. The complaints allege the disparity between public communications and trial outcomes reveals a mischaracterization of the therapeutic profile.

The lawsuits assert that Ultragenyx’s earlier communications led the market and shareholders to expect that key efficacy endpoints would be met, and that the ORBIT data expose contrary findings. Lead counsels argue the company’s portrayal of clinical understanding and program prospects is central to investor claims under Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5. The class actions target purchases of Ultragenyx securities between Aug. 3, 2023 and Dec. 26, 2025 and seek to recover alleged losses tied to disclosures about ORBIT.

Beyond litigation, the ORBIT outcome prompts broader questions about Ultragenyx’s OI development strategy and the interpretation of fracture-rate endpoints in rare-disease trials. Missing a prespecified AFR reduction typically compels sponsors to undertake post-hoc analyses, consider alternative endpoints or additional studies, and engage regulators on next steps. Plaintiffs say those programmatic implications matter to the allegations, while the company’s scientific characterization of the data is now the focus of legal scrutiny.

Law firms issue class action reminders

The Schall Law Firm files a class action complaint and reminds eligible investors of an April 6, 2026 deadline to seek representation in the matter, alleging violations of federal securities laws tied to the ORBIT disclosures. The firm encourages affected shareholders to contact it for a free consultation regarding potential participation.

DJS Law Group issues a similar notice, urging shareholders who purchased RARE shares during the class period to consider lead plaintiff appointments and preserve records ahead of the April 6, 2026 deadline. Both firms stress that recoveries depend on court processes, proof of loss and any eventual settlement or trial outcome.